Haemonetics Corp. (HAE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Masimo Corp.

Haemonetics Corp.

Shockwave Medical, Inc.

Envista Holdings Corp.

Natera, Inc.

QuidelOrtho Corp.

Bausch + Lomb Corp.

Inspire Medical Systems, Inc.

Bio-Rad Laboratories, Inc.

Lantheus Holdings, Inc.

Dentsply Sirona, Inc.

Why is Haemonetics Corp. ?

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.96

Poor long term growth as Net Sales has grown by an annual rate of 7.32% and Operating profit at 8.03% over the last 5 years

Flat results in Jun 25

DEBT-EQUITY RATIO (HY) Highest at 105.62 %
INTEREST(Q) At USD 4.07 MM has Grown at inf%
INVENTORY TURNOVER RATIO(HY) Lowest at 1.69 times

With ROCE of 12.30%, it has a attractive valuation with a 2.47 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -3.93%, its profits have risen by 1.5% ; the PEG ratio of the company is 8.4

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -3.93% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Haemonetics Corp. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Haemonetics Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Haemonetics Corp.

0.36%

-0.09

53.44%

S&P 500

13.22%

0.64

20.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.32%

EBIT Growth (5y)

8.03%

EBIT to Interest (avg)

8.96

Debt to EBITDA (avg)

2.49

Net Debt to Equity (avg)

1.13

Sales to Capital Employed (avg)

0.69

Tax Ratio

20.93%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

10.56%

ROE (avg)

14.77%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.12

EV to EBIT

20.06

EV to EBITDA

13.04

EV to Capital Employed

2.47

EV to Sales

3.17

PEG Ratio

8.36

Dividend Yield

ROCE (Latest)

12.30%

ROE (Latest)

18.58%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

ROCE(HY)

Highest at 18.27%

RAW MATERIAL COST(Y)

Fallen by -13.43% (YoY

CASH AND EQV(HY)

Highest at USD 599.66 MM

-6What is not working for the Company

DEBT-EQUITY RATIO (HY)

Highest at 105.62 %

INTEREST(Q)

At USD 4.07 MM has Grown at inf%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.69 times

NET SALES(Q)

Lowest at USD 321.39 MM

Here's what is working for Haemonetics Corp.

Cash and Eqv

Highest at USD 599.66 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by -13.43% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Haemonetics Corp.

Interest

At USD 4.07 MM has Grown at inf%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Debt-Equity Ratio

Highest at 105.62 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Net Sales

Lowest at USD 321.39 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Inventory Turnover Ratio

Lowest at 1.69 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio